

HETEROCYCLES, Vol. 96, No. 12, 2018, pp. 2126 - 2134. © 2018 The Japan Institute of Heterocyclic Chemistry
Received, 15th October, 2018, Accepted, 29th November, 2018, Published online, 20th December, 2018
DOI: 10.3987/COM-18-14002

MULTIGRAM-SCALE AND COLUMN CHROMATOGRAPHY-FREE SYNTHESIS OF L-AZETIDINE-2-CARBOXYLIC ACID FOR THE SYNTHESIS OF NICOTIANAMINE AND ITS DERIVATIVES

Tomohiro Takaishi,¹ Kyosuke Wakisaka,¹ Christopher J. Vavricka,² Hiromasa Kiyota,¹ and Minoru Izumi^{1*}

¹ Graduate School of Environmental and Life Science, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan. ² Graduate School of Science, Technology and Innovation, Kobe University, 1-1 Rokkodai, Nada, Kobe 657-8501, Japan. E-mail: mizumi@okayama-u.ac.jp.

Abstract – Multigram-scale synthesis of L-azetidine-2-carboxylic acid from L-aspartic acid was achieved in 13 conventional synthetic steps, without the need for purification by silica-gel column chromatography and expensive reagents. Nicotianamine and its fluorescence-labeled derivatives could be obtained from this synthetic strategy.

Nicotianamine (**1**),¹ which is biosynthesized from three molecules of (*S*)-adenosyl-L-methionine via nicotianamine synthase, is a metal-chelating molecule ubiquitous in higher plants.² L-Azetidine-2-carboxylic acid (L-Aze **2**) is a key chemical precursor to nicotianamine, deoxymugineic acid, as well as nicotinic receptor tracers.³ There are many reports on the organic synthesis of L-Aze and its derivatives; for example, Futamura *et al.* reported an efficient route to L-Aze in five steps (total yield: 48%) via malonic ester intermediates.⁴ Recently, Bouzaoui *et al.* has reported the synthesis of L-Aze using the (2-trimethylsilyl)ethanesulfonyl (SES) protecting group as a leaving group on the hydroxy function and as an activator for the amine function.⁵ It is necessary to develop a large-scale synthesis to enable medicine and agrochemical studies; however, it is desirable to obtain L-Aze and its derivatives without use of hydrogenolysis by Pd-C, selective enzymatic hydrolysis, and/or expensive reagents. In this study, we described an efficient and cheap route to L-Aze via L-aspartic acid intermediates and its application to the synthesis of nicotianamine.






Figure 1. Nicotianamine (1) and L-azetidine-2-carboxylic acid (2)

Commercially available 1-*tert*-butyl L-aspartate or L-homoserine have recently been used as starting material for the synthesis of L-Aze and its derivatives. Bouazaoui *et al.* has reported good results using 1-*tert*-butyl L-aspartate and SES as key reagents,⁵ however, the newly reported synthesis of this study started from 1 mole of L-aspartic acid (3) to reduce cost (Scheme 1). Methyl *N*-Boc-L-aspartate (4) was obtained in 99% yield over two steps after selective esterification using chlorotrimethylsilane (TMSCl) and protection of the amino group using di-*tert*-butyl dicarbonate ((Boc)₂O).⁶ *tert*-Butyl esterification of α -carboxyl group followed by saponification of the methoxycarbonyl group located at β -position, produced the desired compound 6 in 92% yield (2 steps from 4). Methyl *N*-Boc-L-aspartate and its derivatives could be easily separated by pH-controlled extraction from the reaction mixture without the need for silica-gel column chromatography. A chromatography-free process is idea for large-scale synthesis. Reduction of the carboxy moiety with NaBH₄ via the formation of a mixed acid anhydride derivative, followed by reaction with ethyl chloroformate in the presence of triethylamine, gave *tert*-butyl *N*-Boc-L-homoserine (7) in 84% yield. Among the many kinds of C-N bond formation for intramolecular cyclization (Mitsunobu reaction, reductive amination, etc.), direct *N*-alkylation was selected. Two steps, reaction of hydroxy group with *p*-TsCl followed by iodination, were necessary to afford the desired intermediate (8) in 91% yield (Scheme 1, overall yield of 77%, 7 steps from 3).



Scheme 1. Reagents and conditions: (a) TMSCl, MeOH, rt; (b) (Boc)₂O, dioxane, NaHCO₃ aq., 0 °C then rt, 99% (2 steps); (c) DCC, DMAP, *t*-BuOH, DCE, rt, 92%; (d) 1 M NaOH aq., acetone, rt, quant; (e) ethyl chloroformate, TEA, THF, 0 °C then NaBH₄, 0 °C then rt, 84%; (f) TsCl, TEA, DMAP; (g) NaI, acetone, rt, 91% (2 steps).

In the case of *N*-Boc derivatives, intramolecular cyclization did not occur due to low nucleophilicity of the *N*-Boc-amino group. Therefore, the amino protective group was changed Ts instead of SES or Ns groups^{5,7} as TsCl was much cheaper than SESCl or NsCl. *N*-Ts intermediate (**10**) was obtained quantitatively after deprotection by TMSCl followed by TsCl amino re-protection. Cyclization of **10** was performed using Cs₂CO₃ in MeCN to give *N*-Ts-L-Aze (**11**) in 94% yield. Ts deprotection via Mg in MeOH⁷ and *tert*-butyl deprotection via TFA afforded multigram quantities of L-Aze (**2**), obtained over 13 steps with an overall yield of 49% from L-aspartic acid **3** (Scheme 2).



Scheme 2. Reagents and conditions: (a) TMSCl, THF, MeOH, rt, quant; (b) TsCl, TEA, DMAP, DCE, 0 °C then rt, 94%; (c) Cs₂CO₃, MeCN, rt, quant; (d) Mg, MeOH, rt, 68%; (e) TFA, H₂O, DCE, quant.

Next, we compared the synthesis of nicotianamine (**1**) according to Bouazaoui's method⁸ (Scheme 3). In the first alkylation step, *tert*-butyl L-azetidine-2-carboxylate (**12**) was successfully *N*-alkylated with the iodide **8**, together with DIPEA⁹ in MeCN, to provide **13** in 60% yield. After deprotection of the *N*-Boc group quantitatively (**14**), the targeted compound (**15**) was obtained in 42% yield by the second *N*-alkylation step. Removal of the Boc group and *tert*-butyl groups proceeded without difficulty by TFA treatment to afford nicotianamine (**1**) quantitatively after lyophilization as a white powder. In order to identify the localization of nicotianamine in plant, we synthesized fluorescence-labeled nicotianamine (**FITC-1**) as chemical probe. After fluorescence labeling of the secondary amino group by fluorescein isothiocyanate, deprotection of *tert*-butyl groups proceeded by TFA treatment to afford FITC-labeled nicotianamine (**FITC-1**).

under reduced pressure. To a mixture of the residue in 1,4-dioxane (67 mL) and sat. NaHCO₃ aq. (33 mL) was added a solution of di-*tert*-butyl dicarbonate (24.0 g, 0.11 mmol) in 1,4-dioxane (10 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h and then stirred at room temperature for 24 h. The 1,4-dioxane was removed on a rotary evaporator, the residue was poured onto ice-water (100 mL) and the cold solution was washed with CHCl₃ (100 mL × 3) to separate nonacidic compounds. The aqueous solution was acidified (pH 2.5) with a solution of 1 M HCl aq., and extracted with CHCl₃ (100 mL × 5). The combined CHCl₃ extracts were washed with water and dried. The solvent was removed on a rotary evaporator to give the *N*-Boc-monomethyl ester as a colorless liquid (**4**, 24.8 g, 0.11 mmol, quant); ¹H NMR (CDCl₃) δ 1.45 (9H, s, *t*-Bu), 2.81 (1H, dd, *J* = 4.8, 17.2 Hz, H β -a), 3.01 (1H, dd, *J* = 4.8, 17.2 Hz, H β -b), 3.64 (3H, s, CO₂Me), 4.20 (1H, t, *J* = 5.5 Hz, H α); ¹³C NMR (CDCl₃) δ 28.4, 36.6, 51.9, 54.3, 79.5, 156.0, 169.3, 173.2.

***tert*-Butyl *N*-Boc-*L*-aspartate 4-methyl ester (5).** To a solution of compound **4** (88.2 g, 0.36 mol) in DCE (400 mL) were added DCC (81.0 g, 0.40 mol), DMAP (4.36 g, 0.036 mol) and *tert*-butyl alcohol (73.0 mL, 0.72 mol) at 0 °C. The resulting mixture was stirred at room temperature for 24 h, and then concentrated under reduced pressure. The residue was dissolved into AcOEt (500 mL) and the cold solution was washed with a solution of 1 M HCl aq. (250 mL), and brine (250 mL), and dried. The solvent was removed on a rotary evaporator to give the *N*-Boc-diester as a colorless solid (99.9 g, 92%); mp 68-70 °C; ¹H NMR (CDCl₃) δ 1.45 (12H, s, *t*-Bu), 1.68 (6H, s, *t*-Bu), 2.81 (1H, dd, *J* = 4.8, 17.2 Hz, H β -a), 3.01 (1 H, dd, *J* = 4.8, 17.2 Hz, H β -b), 3.64 (3H, s, CO₂Me), 4.20 (1H, t, *J* = 5.5 Hz, H α); ¹³C NMR (CDCl₃) δ 28.4, 36.1, 51.7, 54.2, 79.4, 155.7, 169.1, 169.7.

***tert*-Butyl (*S*)-2-(*tert*-butoxycarbonylamino)-4-hydroxybutanoate (6).** To a solution of compound **5** (99.9 g, 0.33 mol) in acetone (400 mL) and H₂O (50 mL) was added 1 M NaOH aq. (175 mL) at room temperature. The reaction mixture was stirred at room temperature for 4.5 h, and then concentrated under reduced pressure. The residue was solved in CHCl₃ (400 mL), and the solution was washed with 1 M HCl aq. (100 mL × 3) and dried. The solvent was removed on a rotary evaporator, and the residue was crystallized from hexane to give the *tert*-butyl *N*-Boc-*L*-aspartate **6** as a colorless solid (84.4 g, quant); mp 98-102 °C; ¹H NMR (CDCl₃) δ 1.45 (s, 12 H, *t*-Bu), 1.68 (6H, s, *t*-Bu), 2.81 (1H, dd, *J* = 4.4, 17.0 Hz, H β -a), 3.01 (1H, dd, *J* = 4.4, 17.0 Hz, H β -b), 4.40-4.49 (1H, m, H α), 5.46 (1H, d, *J* = 7.2 Hz, NH); ¹³C NMR (CDCl₃) δ 28.4, 28.7, 36.1, 54.0, 79.5, 82.1, 155.9, 169.8, 173.2.

***O*-*tert*-Butyl-*N*-*tert*-butoxycarbonyl-*L*-homoserine (7).** To a solution of compound **6** (12.4 g, 42.8 mmol) in THF (300 mL) were added ethyl chloroformate (5.1 mL, 47.1 mmol) and TEA (6.6 mL, 47.1 mmol) was added at 0 °C. The reaction mixture was stirred at room temperature for 1.5 h, and then NaBH₄ (2.3 g, 60.4 mmol) was added portionwise. The reaction mixture was stirred for 12 h, and the

solvent was evaporated *in vacuo*, and the crude was dissolved in AcOEt (250 mL). The organic layer was washed successively with a 10% citric acid solution (300 mL), a sat. NaHCO₃ aq. (300 mL) and brine (200 mL). The organic layer was dried with anhydrous MgSO₄ and concentrated to afford a colourless oil **7** (9.5 g, 84%); ¹H NMR (CDCl₃) δ 1.41 (9H, s, *t*-Bu), 1.43 (9H, s, *t*-Bu), 1.51-1.59 (1H, m, Hβ-a), 2.04-2.18 (1H, m, Hβ-b), 3.60-3.61-3.81 (2H, m, Hγ), 4.29-4.38 (1H, m, Hα), 5.30-5.38 (1H, m, NH); ¹³C NMR (CDCl₃) δ 27.9, 28.3, 36.4, 52.3, 58.7, 80.3, 82.3, 156.6, 172.0.

tert-Butyl *N*-tert-butoxycarbonyl-(*S*)-2-amino-4-iodobutanoate (8). To a solution of **7** (6.06 g, 22.0 mmol) in DCE (100 mL) were added DMAP (0.26 g, 2.20 mmol), Et₃N (15.3 mL, 110 mmol), TsCl (8.41 g, 44.0 mmol) at 0 °C, followed by stirring at room temperature for 4 h. The reaction mixture was evaporated *in vacuo*, the residue was dissolved in AcOEt (200 mL), washed with 1 M HCl aq. (200 mL × 3), followed by washing with a sat. NaHCO₃ aq. (200 mL × 2), and finally with brine. The organic layer was dried with MgSO₄ and concentrated to afford a yellow oil as a residue. Without any purification, a portion of the residue was used. To a solution of the residue in acetone (50 mL) was added NaI (9.93 g, 66.0 mmol). The reaction mixture was stirred with light interception for 24 h, and poured into cooled water (100 mL), followed by extracted with AcOEt (100 mL). The organic layer was washed with brine, dried with MgSO₄, and concentrated *in vacuo* to afford a yellow oil **8** (7.74 g, 91%); ¹H NMR (CDCl₃) δ 1.47 (9H, s, *t*-Bu), 1.49 (9H, s, *t*-Bu), 2.10-2.18 (1H, m, Hβ-a), 2.32-2.46 (1H, m, Hβ-b), 3.11-3.21 (2H, m, Hγ), 4.18 (1H, dd, *J* = 6.4, 11.6 Hz, Hα), 5.07 (1H, d, *J* = 7.2 Hz, NH); ¹³C NMR (CDCl₃) δ 14.1, 27.8, 28.3, 37.7, 60.4, 80.0, 82.5, 155.3, 170.6.

tert-Butyl *N*-(*p*-toluenesulfonyl)-(*S*)-2-amino-4-iodobutanoate (10). To a solution of compound **8** (5.97 g, 15.5 mmol) in THF (50 mL) and MeOH (10 mL) was added TMSCl (10 mL). The reaction mixture was stirred at room temperature for 24 h, and then was evaporated to obtain a residue as a compound **9** quantitatively. Without any purification, compound **9** was used for next reaction. To a solution of the residue as a compound **9** in DCE (30 mL) were added TsCl (2.96 g, 15.5 mmol), TEA (6.5 mL, 46.5 mmol) and DMAP (0.19 g, 1.55 mmol). The reaction mixture was stirred at room temperature for 3 h, and concentrated *in vacuo*. The residue was dissolved in Et₂O (100 mL) and washed with a solution of 1 M HCl aq. (100 mL × 2), followed by a sat. NaHCO₃ aq. (100 mL), and then with brine (300 mL). The organic layer was dried with MgSO₄ and concentrated to afford a yellow oil (6.37 g, 94 %); ¹H NMR (CDCl₃) δ 1.26 (9H, s, *t*-Bu), 2.03-2.26 (2H, m, Hβ), 2.40 (3H, s, Ph-CH₃), 3.16-3.27 (2H, m, Hγ), 3.72-3.85 (1H, m, Hα), 5.17 (1H, d, *J* = 9.2 Hz, NH), 7.29 (2H, d, *J* = 8.0 Hz, Ph), 7.73 (2H, d, *J* = 8.0 Hz, Ph); ¹³C NMR (CDCl₃) δ 14.1, 21.7, 28.0, 28.3, 37.7, 60.4, 80.0, 82.5, 127.4, 129.8, 136.1, 144.0, 155.3, 170.6.

tert-Butyl *N*-(*p*-toluenesulfonyl)-(*S*)-azetidine-2-carboxylate (11). To a solution of **10** (3.10 g, 7.0

mmol) in MeCN (20 mL) was added Cs₂CO₃ (4.50 g, 14.0 mmol) at room temperature. The reaction mixture was stirred at room temperature for 24 h. The reaction mixture was evaporated *in vacuo*, the residue was dissolved in AcOEt (50 mL), washed with a solution of 1 M HCl aq. (50 mL × 2) and then with brine. The organic layer was dried with MgSO₄ and concentrated to afford a colorless solid **11** (2.30 g, quant); mp 78-82 °C; ¹H NMR (CDCl₃) δ 1.43 (9H, s, *t*-Bu), 2.18-2.24 (1H, m, Hβ-a), 2.29-2.37 (1H, m, Hβ-b), 2.43 (3H, s, Ph-CH₃), 3.66-3.74 (1H, m, Hγ-a), 3.82-3.91 (1H, m, Hγ-b), 4.46 (1H, dd, *J* = 8.0, 9.2 Hz, Hα), 7.33 (2H, d, *J* = 8.4 Hz, Ph), 7.78 (2H, d, *J* = 8.4 Hz, Ph); ¹³C NMR (CDCl₃) δ 23.2, 27.7, 44.2, 58.3, 81.0, 127.4, 129.8, 136.1, 144.0, 172.4.

tert-Butyl (S)-azetidine-2-carboxylate (12). To a solution of compound **11** (2.4 g, 76.0 mmol) in MeOH (20 mL) was added Mg turnings (9.2 g, 382 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 h. After cooling the reaction mixture to 0 °C, brine (50 mL) was added. After filtration, a solution was extracted with CHCl₃ (100 mL). The organic layer was dried with MgSO₄ and concentrated to afford a yellow oil (8.2 g, 68 %); ¹H NMR (CDCl₃) δ 1.42 (9H, s, *t*-Bu), 2.25-2.33 (1H, m, Hβ-a), 2.61-2.69 (1H, m, Hβ-b), 3.52-3.81 (2H, m, Hγ), 4.40-4.49 (1H, m, Hα), 5.22 (1H, s, NH); ¹³C NMR (CDCl₃) δ 23.2, 27.7, 44.2, 58.3, 81.0, 172.4.

(S)-Azetidine-2-carboxylic acid (2). To a solution of compound **12** (1.57 g, 10.0 mmol) in DCE (10 mL) were added water (10 mL) and TFA (10 mL) at 0 °C. The reaction mixture was stirred at room temperature for 6 h, and then 28% NH₃ aq. was added carefully 0 °C. After freeze-drying, compound **2** was obtained as a pale brown solid (1.01 g, quant); mp 216-218 °C (lit.,⁵ mp 210 °C); [α]_D²⁰ -117.0 (c 0.1, H₂O) {lit.,⁵ [α]_D²⁴ -107.6 (c 3.1, H₂O)}; ¹H NMR (D₂O) δ 2.29-2.51 (1H, m, Hβ-a), 2.69-2.85 (1H, m, Hβ-b), 3.54-3.83 (2H, m, Hγ), 4.39-4.51 (1H, m, Hα); ¹³C NMR (D₂O) δ 23.1, 42.1, 58.4, 172.1.

tert-Butyl (S)-1-[(S)-3-(tert-butoxycarbonylamino)-4-tert-butoxy-4-oxobutyl]azetidine-2-carboxylate (13). Reaction was followed by Bouazaoui's method.⁸ A solution of compound **12** (0.11 g, 0.72 mmol) in anhydrous MeCN (5 mL) was added to compound **8** (0.28 g, 0.72 mmol) dissolved in anhydrous MeCN (2 mL). The reaction mixture was stirred for 30 min under argon. Freshly distilled diisopropylethylamine (0.24 mL, 1.44 mmol) was added and the reaction mixture was diluted with anhydrous MeCN (10 mL). The reaction mixture was heated to 55 °C and stirred for 24 h. The mixture was concentrated and the crude was dissolved in AcOEt (10 mL). The organic layer was washed with 1M HCl aq., brine and distilled water. The organic phase was dried with MgSO₄, filtered and concentrated to afford a yellow oil. The target compound was purified by chromatography on silica gel (hexane/AcOEt, 4:1 to 1:1) to afford a yellow oil (0.18 g, 60%); ¹H NMR (CDCl₃) δ 1.45 (9H, s, *t*-Bu), 1.47 (18H, s, *t*-Bu × 2), 1.72-1.89 (2H, m, H-2), 2.04-2.28 (2H, m, H-1), 2.42-2.85 (2H, m, Hβ), 3.31-3.35 (2H, m, H-3), 3.52-3.83 (2H, m, Hα, and Hγ); ¹³C NMR (CDCl₃) δ 21.3, 28.0, 28.1, 28.3, 31.1, 50.8, 53.3, 55.2, 62.0,

65.2, 80.0, 80.3, 172.1, 174.2

tert-Butyl (S)-1-[(S)-3-amino-4-tert-butoxy-4-oxobutyl]azetidone-2-carboxylate (14). To a solution of compound **13** (67.6 mg, 0.16 mmol) in a mixture of THF (1 mL) and MeOH (0.2 mL) was added TMSCl (0.2 mL) at 0 °C. The reaction mixture was stirred for 24 h, filtered through Celite and concentrated to afford a pale yellow oil (50.3 mg, quant); ¹H NMR (CDCl₃) δ 1.43-1.55 (1H, m), 1.45 (9H, s, *t*-Bu), 1.47 (9H, s, *t*-Bu), 1.72-2.08 (2H, m, H-2), 2.29-2.52 (2H, m, H-1), 2.74-2.79 (2H, m, Hβ), 3.28-3.37 (1H, m, H-3), 3.44-3.53 (3H, m, Hα and Hγ); ¹³C NMR (CDCl₃) δ 21.0, 28.0, 28.3, 31.1, 50.4, 53.1, 55.0, 65.2, 80.0, 80.3, 170.3, 174.0.

tert-Butyl

(S)-1-[(S)-3-{N-[(S)-3-(tert-butoxycarbonylamino)-4-oxohexyl]-2-tert-butoxycarbonylamino}-4-tert-butoxy-4-oxobutyl]azetidone-2-carboxylate (15). To a solution of **14** (50.3 mg, 0.16 mmol) in MeCN (1 mL) was added Cs₂CO₃ (208 mg, 0.64 mmol) at room temperature, followed by stirring at room temperature for 30 min. A solution of **8** (52.9 mg, 0.19 mmol) in MeCN (1 mL) was added into the reaction mixture, followed by heating at 55 °C for 1 h. The reaction mixture was stirred for 24 h at room temperature, concentrated and then dissolved in AcOEt (20 mL). The organic layer was washed with 1M HCl aq. and brine, then dried with MgSO₄ and concentrated. Compound **15** was obtained after silica gel chromatography (hexane/AcOEt, 2:1 to 1:1) as a yellow oil (40.0 mg, 42%); ¹H NMR (CDCl₃) δ 1.43 (s, 18H, s, *t*-Bu × 2), 1.47 (9H, s, *t*-Bu), 1.51 (s, 9H, *t*-Bu), 1.56-1.80 (2H, m, H-2), 1.92-2.40 (2H, m, H-1 and H-2'), 2.61-2.95 (3H, m, Hβ and H-1'), 3.50-3.84 (4H, m, Hα, Hγ and H-3), 4.01-4.19 (1H, m, H-3'); ¹³C NMR (CDCl₃): δ 16.3, 17.8, 18.0, 18.3, 21.0, 26.9, 42.5, 44.0, 54.4, 57.9, 65.6, 170.6, 171.4, 173.0.

Nicotianamine (1). To a solution of **15** (195 mg, 0.34 mmol) in a mixture of DCE (10 mL) and H₂O (0.1 mL) was added TFA (1 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 3 h. DCE was evaporated and the resulting mixture was neutralized by the addition of 28% NH₃ aq. The crude was dissolved in distilled water (3 mL) and the aqueous layer washed with Et₂O (3 mL × 3). After freeze-drying, compound **1** was obtained as a white solid (103 mg, quant); mp 220-222 °C (lit.,⁸ mp 218-220 °C); [α]_D²⁰ -56.0 (c 0.1, H₂O) {lit.,⁸ [α]_D²⁴ -55.6 (c 0.81, H₂O)}; ¹H NMR (D₂O) δ 1.93-2.03 (2H, m, H-2), 2.05-2.13 (2H, m, H-2'), 2.28-2.33 (2H, m, H-1 and H-1'), 2.62-2.69 (2H, m, Hβ), 3.63-3.89 (4H, m, Hγ, H-3 and H-3'), 4.01-4.10 (1H, m, Hα); ¹³C NMR (D₂O) δ 16.3, 17.8, 21.0, 26.9, 42.5, 44.0, 54.4, 57.9, 65.6, 170.6, 171.4, 173.0.

FITC-labeled Nicotianamine (FITC-1). To a solution of **15** (140 mg, 0.18 mmol) in a mixture of THF (10 mL) was added fluorescein 5-isothiocyanate (70 mg, 0.18 mmol) at 0 °C, and the mixture was stirred at room temperature. After 3 h, water was added to the reaction mixture, and then solvent was evaporated. The crude was dissolved in distilled DCE (3 mL), followed by the addition of H₂O (1 mL) and TFA (1

mL). The solution was evaporated again and the remaining was neutralized by addition of TEA. The crude was dissolved in distilled water (3 mL) and the aqueous layer washed with Et₂O (3 mL × 3). Compound **FITC-1** was obtained after silica gel chromatography (CHCl₃/MeOH, 4:1) as a yellow oil (49 mg, 98%); ¹H NMR (DMSO) δ 1.95–2.28 (4H, m, H-2 and H-2'), 2.45–2.79 (6H, m, Hβ and H-1 and H-1'), 3.63–3.99 (4H, m, Hγ, H-3 and H-3'), 4.17–4.25 (1H, m, Hα), 6.58–6.72 (6H, m, fluorescein), 7.29 (1H, d, *J* = 1.0 Hz, fluorescein), 7.80 (1H, d, *J* = 1.0 Hz, fluorescein), 8.00 (1H, s, fluorescein); ¹³C NMR (DMSO) δ 16.3, 17.8, 21.0, 26.9, 42.5, 44.0, 54.4, 57.9, 65.6, 84.8, 105.7, 107.7, 109.6, 112.7, 124.0, 126.1, 129.0, 130.0, 135.5, 151.9, 159.6, 168.7, 170.6, 171.4, 173.0.

ACKNOWLEDGEMENTS

The authors are grateful to Dr. Kei Matsumoto at Division of Instrumental Analysis, Okayama University for the NMR spectral measurements. The authors are also grateful to Miss Chieri Inoue and Miss Yumi Okamoto at Graduate School of Environmental and Life Science, Okayama University for the NMR spectral measurements. Financial support from KAKENHI (No. 17K07772) and Wesco Scientific Promotion Foundation are acknowledged.

REFERENCES

1. M. Noma, M. Noguchi, and E. Tamaki, *Tetrahedron Lett.*, 1971, **12**, 2017.
2. (a) M. Takahashi, Y. Terada, I. Nakai, H. Nakanishi, E. Yoshimura, S. Mori, and N. K. Nishizawa, *Plant Cell*, 2003, **15**, 1263; (b) L. Zheng, Z. Cheng, C. Ai, X. Jiang, X. Bei, Y. Zheng, R. P. Glahn, R. M. Welch, D. D. Miller, X. G. Lei, and H. Shou, *PLoS ONE*, 2010, **5**, e10190. doi:10.1371/journal.pone.0010190.
3. (a) E. Brenner, R. M. Baldwin, and G. Tamagnan, *Tetrahedron Lett.*, 2004, **45**, 3607; (b) K. Namba, Y. Murata, M. Horikawa, T. Iwashita, and S. Kusumoto, *Angew. Chem. Int. Ed.*, 2007, **46**, 7060.
4. Y. Futamura, M. Kurokawa, R. Obata, S. Nishiyama, and T. Sugai, *Biosci. Biotechnol. Biochem.*, 2005, **69**, 1892.
5. M. Bouazaoui, J. Martinez, and F. Cavelier, *Eur. J. Org. Chem.*, 2009, 2729.
6. T. Takaishi, M. Izumi, R. Ota, C. Inoue, H. Kiyota, and K. Fukase, *Nat. Prod. Commun.*, 2017, **12**, 247.
7. D. Alonso and P. Andersson, *J. Org. Chem.*, 1998, **63**, 9455.
8. M. Bouazaoui, M. Larrouy, J. Martinez, and F. Cavelier, *Eur. J. Org. Chem.*, 2010, 6609.
9. T. Shioiri, N. Irako, S. Sakakihara, F. Matsuura, and Y. Hamada, *Heterocycles*, 1997, **44**, 519.